• CSBTA Pharmacokinetics in MASH Mice

  2026-10-07

  A 2025 study integrated plasma pharmacokinetics, tissue distribution, cellular accumulation, metabolism, and transporter biology to examine how MASH-like pathology alters exposure to Corydalis saxicola Bunting total alkaloids. Its findings indicate that disease state and repeated administration can increase systemic and hepatic exposure, while changes in CYP450 enzymes and transporters may contribute to pharmacokinetic variability.

• Ibrutinib (PCI-32765): BTK Evidence in Context

  2026-10-07

  Ibrutinib (PCI-32765) is a covalent BTK inhibitor widely used to study B-cell receptor signaling inhibition. This evidence-focused guide distinguishes established B-cell pharmacology from the separate ATRX-deficient glioma findings reported for RTK and PDGFR inhibitors.

• Protein A/G Magnetic Beads: Evidence and Limits

  2026-10-06

  Protein A/G Magnetic Beads support antibody-mediated enrichment in immunoprecipitation and related assays, but the beads themselves do not prove a protein interaction or biological mechanism. This overview examines their binding principle, how co-immunoprecipitation evidence should be interpreted, what the supplied vascular study shows, and where product claims and translational conclusions remain limited.

• Fluorescein TSA in Cardiac Inflammation Research

  2026-10-06

  A source-grounded overview of how fluorescein tyramide amplification may support spatial studies of doxorubicin cardiotoxicity, alongside an evidence-based assessment of the mechanism, interpretive value, and limitations of the available research.

• Protein A/G Magnetic Beads: Product Overview

  2026-10-05

  Protein A/G Magnetic Beads (SKU K1305) are supplier-described magnetic affinity particles containing recombinant Protein A and Protein G for Fc-region antibody binding. No matched paper evidence is available in the supplied material, so performance, specificity, and assay outcomes cannot be independently assessed.

• From Binding Events to Translational Mechanism

  2026-10-05

  A source-grounded perspective on how Protein A/G Magnetic Beads can support mechanistic immunoprecipitation, co-IP, and Ch-IP strategies—while keeping association data, causal biology, and clinical translation analytically distinct.

• Bromodomain Inhibitor (+)-JQ1 and Ferroptosis

  2026-10-04

  Bromodomain Inhibitor, (+)-JQ1 is a selective BET bromodomain inhibitor whose value extends beyond conventional apoptosis models. This evidence-focused analysis examines how BRD4, ROS, FSP1, ferroptosis, and cell context shape interpretation of the latest mechanistic findings.

• Verapamil HCl: Evidence, Mechanisms, and Limits

  2026-10-03

  A five-question, source-grounded overview of Verapamil HCl, covering calcium-channel pharmacology, the TXNIP–bone remodeling study, evidence quality, interpretation, translational scope, and key limitations.

• (-)-Arctigenin: From NF-κB Biology to Translation

  2026-10-01

  A translational framework for using (-)-Arctigenin as an NF-κB and MEK1 pharmacological probe, connecting inflammatory signaling with macrophage–tumor communication while distinguishing established evidence from testable hypotheses.

• Meropenem Workflows for Resistant Bacterial Models

  2026-10-01

  Build reproducible Meropenem assays for susceptibility testing, time-kill analysis, resistance selection, and translational infection studies. This workflow emphasizes exposure-aware design, solvent control, and the practical separation of free-drug activity from nanoparticle-delivery effects.

• Fluorescein TSA Fluorescence System Kit Guide

  2026-09-30

  This scenario-driven guide explains how Fluorescein TSA Fluorescence System Kit, SKU K1050, can improve fluorescence detection of low-abundance biomolecules in fixed cells and tissues. It covers mechanism, compatibility, protocol controls, data interpretation, storage, and practical vendor-selection criteria.

• Arctigenin N2399: Reliable Cell Assay Workflows

  2026-09-30

  This scenario-driven guide explains how Arctigenin (SKU N2399) can support better-controlled viability, proliferation, cytotoxicity, and pathway assays. It focuses on solvent compatibility, concentration design, mechanistic interpretation, and supplier selection while distinguishing product data from findings reported in breast cancer research.

• MEK1/2–c-Myc:MAX Control of TERT in Stem Cells

  2026-09-29

  A recent human pluripotent stem-cell study identifies a signaling–chromatin mechanism in which MEK/ERK activity and c-Myc:MAX cooperate to maintain TERT transcription. The findings connect kinase inhibition, PRC2-associated H3K27 methylation, and reduced MAX occupancy at the TERT promoter, providing a framework for interpreting c-Myc transcription factor inhibition in telomere biology.

• DiscoveryProbe FDA-Approved Drug Library Guide

  2026-09-29

  The DiscoveryProbe FDA-approved Drug Library is a 2,320-compound FDA-approved bioactive compound library for drug repositioning screening, high-throughput screening, and pharmacological target identification. Its pre-dissolved 10 mM DMSO format supports standardized assay setup, while the cabozantinib study illustrates how approved-drug screening can generate mechanism-focused hypotheses.

• Patient-Derived Gastric Cancer Assembloids

  2026-09-28

  This 2025 study develops gastric cancer assembloids that combine patient-matched tumor organoids with separately expanded stromal cell subpopulations. The model reveals that stromal composition changes transcriptional programs and drug sensitivity, providing a more physiologically informative platform for tumor–stroma research and personalized treatment studies.

8603 records 1/574 page Next 12345 下5页 Last page